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 Psychopathology influences smoking cessation treatment. 
 The MMPI-2-RF is a valid and reliable instrument to assess phychopathology. 
 The scales of the MMPI-2-RF are used to predict smoking in smokers seeking 
treatment. 







People with psychopathology experience high rates of smoking and have more 
2 
trouble quitting. The Minnesota Multiphasic Personality Inventory-2 Restructured Form 
3 
(MMPI-2-RF; Tellegen & Ben-Porath, 2008/2009) is a valid and reliable instrument for 
4 
the assessment of psychopathology. In this study, we examined the ability of the MMPI-
5 
2-RF to assess psychopathology and to predict smoking cessation outcomes in a sample 
6 
of 281 smokers seeking psychological treatment to stop smoking at the end of treatment 
7 
and at 6- and 12-month follow-ups. Results showed that T-scores < 65 on 
8 
Disaffiliativeness (DSF) scale were associated with a higher likelihood of smoking at 
9 
the end of treatment, and T-scores ≥ 65 on Neurological Complaints (NUC) scale were 
10 
associated with a higher likelihood of smoking at the 12-month follow-up, after 
11 
controlling for the effect of age and initial levels of nicotine dependence. The results 
12 
highlight the usefulness of the MMPI-2-RF in the field of smoking cessation treatment.  
13 
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Tobacco use is the leading preventable cause of morbidity and mortality in high 
27 
income countries. Nearly six million people worldwide die each year because of 
28 
tobacco due to its direct relation with different diseases (e.g., lung cancer, 
29 
cardiovascular disorders, emphysema, etc.) (United States Department of Health and 
30 
Human Services [USDHHS], 2014).  
31 
Evidence indicates that smoking is also related to mental health (Aubin, 
32 
Rollema, Svenson, & Winterer, 2012; Hall, & Prochaska, 2009; Rüther et al., 2014). In 
33 
a study conducted by Lasser et al. (2000) adults with and without mental disorders were 
34 
compared regarding their smoking rates and cessation. The results indicated a dose-
35 
response pattern with smoking rates increasing from individuals with no mental 
36 
disorders to those with past month mental disorders. The same pattern was found when 
37 
assessing smoking cessation outcomes: abstinence rates were higher in those 
38 
participants with no mental disorders and they decreased progressively in those with 
39 
history of mental disorders and those with past month mental disorders.  
40 
People with mental disorders smoke more cigarettes per day and are more 
41 
nicotine dependent (Aubin et al., 2012) with rates of smoking prevalence from two to 
42 
four times higher than in the general population (Rüther et al., 2014). The reasons for 
43 
this high consumption are still unknown. It has been indicated that they might smoke for 
44 
stress relief and enjoyment, to ameliorate the effects of mental health problems and 
45 
medication side effects, to relief boredom or as a tool to facilitate social interactions 
46 
(Campion, Checinski, Nurse, & McNeill, 2008). As a result of this high consumption, 
47 
people with mental disorders have serious physical health problems. Moreover, studies 
48 
suggest that people with mental disorders have more problems quitting smoking, 
49 




Prochaska, 2009). Despite the need for people with mental disorders to stop smoking, 
51 
few studies have evaluated the efficacy of smoking cessation treatments in patients with 
52 
mental disorders (Aubin et al., 2012). Among them, the majority has focused in the 
53 
population of smokers with severe mental disorders (e.g., schizophrenia, bipolar 
54 
disorders). This indicates that more studies are needed for those smokers without a 
55 
diagnosis of mental disorder but who suffer an important level of distress to influence 
56 
their smoking and their smoking cessation. 
57 
One of the difficulties in the study of psychopathology in smokers is the 
58 
diversity of assessment tools used. Historically, the Minnesota Multiphasic Personality 
59 
Inventory (MMPI; Hathaway, & McKinley, 1943) has been the most commonly used 
60 
measure to assess psychopathology. In studies with the MMPI or the MMPI-2, a 
61 
relationship has been found between tobacco and high scores on the Hypomania (Ma) 
62 
(Basile et al., 2004; Evans, Borgatta, & Bohrnstedt, 1967; Lipkus, Barefoot, Williams, 
63 
& Siegler, 1994), Psychopathic Deviate (Pd) (Andrucci, Archer, Pancoast, & Gordon, 
64 
1989; Evans et al., 1967; Jaffe, & Archer, 1987; Leon, Kolotkin, & Korgeski, 1979; 
65 
Lipkus et al., 1994), Hypochondriasis (Hs) (Tappan, & Weybrew, 1982), and 
66 
Depression (D) (Leon et al., 1979) scales. Ames et al. (2005) used various MMPI scales 
67 
to assess neuroticism, anxiety, depression and pessimism traits to predict tobacco 
68 
abstinence in 1,877 smokers undergoing treatment to quit smoking. The results showed 
69 
that high scores on these scales were associated with a lower likelihood of being 
70 
abstinent six months after treatment completion. In general, these studies employed 
71 
some items or scales of the questionnaire, but not the entire scale, and they mainly used 
72 
samples of students, making it difficult to generalize these results to other populations. 
73 
The MMPI-2-RF (Tellegen, & Ben-Porath, 2008/2009) is the latest version of 
74 




that are organized hierarchically. Studies have indicated that the scales within the 
76 
MMPI-2-RF had good convergent and discriminant validity (Ayearst, Sellbom, Trobst, 
77 
& Bagby, 2013; Tellegen, & Ben-Porath, 2008/2009) and it has been found to be useful 
78 
for the assessment of psychopathology (Simms, Casillas, Clark, Watson, & Doebbeling, 
79 
2005; van der Heijden, Egger, & Derksen, 2008). However, to our knowledge, no 
80 
research is available on the assessment of smokers seeking treatment to quit. Taking 
81 
into account the high comorbidity of psychopathology and personality problems with 
82 
smoking and its influence on the process of quitting smoking, using the MMPI-2-RF in 
83 
the context of smoking cessation interventions would be useful to identify, in a 
84 
relatively simple way, those smokers with a higher risk for psychopathological 
85 
problems and treatment failure that may need more attention.  
86 
Thus, the aim of this study was to analyze the utility of the MMPI-2-RF scales, 
87 
as indicators of psychopathology, in the prediction of the outcome of a smoking 
88 




2.1. Participants  
91 
Sociodemographic characteristics of participants are presented in Table 1. All 
92 
participants requested treatment to quit smoking between April 2010 and December 
93 
2012. Of the 594 people who requested information, 134 just wanted information about 
94 
the program, 10 were abstinent, 47 were interested in the smoking cessation 
95 
intervention by mail (which is also offered by our Unit), and 19 were not located. 
96 
Finally, 99 smokers were eliminated from the study, due to the following exclusion 
97 
criteria: age under 18 (n = 4); smoking fewer than 10 cigarettes a day (n = 21); not 
98 
completing the pretreatment assessment (n = 36); diagnosis of a severe mental disorder 
99 




substances (alcohol, cannabis, cocaine, heroin, etc.) (n = 6); smoking rolling tobacco, 
101 
cigars, or cigarillos (n = 3); having participated in the same program or other efficacious 
102 
psychological or pharmacological treatments to quit smoking in the past year (n = 7); 
103 
suffering from some pathology that implies a high life risk for the person (n = 3); and 
104 
not attending the first group session (n = 5). Of the remaining 285, 4 were eliminated 
105 
from the study because they presented an invalid MMPI-2-RF protocol according to the 
106 
recommended criteria (CNS ≥ 18, TRIN ≥ 80, VRIN ≥ 80, F-r ≥ 120, Fp-r ≥ 100) 
107 
(Tellegen, & Ben-Porath, 2008/2009). The final sample comprised 281 smokers (60.5% 
108 
women; M = 41.80 years, SD = 10.78), with an average pretreatment consumption of 
109 
21.36 cigarettes per day (SD = 7.92). 
110 




2.2.1. Questionnaire about the smoking behavior (Becoña, 1994). 
113 
Composed of 59 items analyzing sociodemographic variables and various 
114 
aspects of the smoking history and behavior.  
115 
2.2.2. Fagerström Test for Nicotine Dependence (FTND) (Heatherton, Kozlowski, 
116 
Frecker, & Fagerström, 1991; adaptation to Spanish of Becoña, & Vázquez, 1998). 
117 
Composed of six items in which scores ≥ 6 are considered to be indicative of 
118 
nicotine dependence (Fagerström, & Furberg, 2008). In the current study, the reliability 
119 
obtained with Cronbach's alpha coefficient was .59, indicating that it has moderate 
120 




2.2.3. MMPI-2-RF (Tellegen, & Ben-Porath, 2008/2009).  
123 
A 338-item self-report questionnaire that provides scores on 51scales. First, 
124 




five scales, the Personality Psychopathology Five (PSY-5), assess personality, 
126 
aggressiveness, psychoticism, disconstraint, negative emotionality, and introversion. In 
127 
addition, two scales measure aesthetic-literary or mechanical-physical interests. Finally, 
128 
measures of psychopathology are organized hierarchically. The Higher-Order (H-O) 
129 
scales, which define the highest level, provide an organizational structure, the 
130 
Restructured Clinical (RC) scales, which are in an intermediate level and analyze 
131 
clinical features, and at the bottom of the hierarchy, the Specific Problems (SP) scales 
132 
that provide a more fully developed and detailed assessment. The H-O scales are three 
133 
scales for the assessment of emotional or internalization dysfunction, thought 
134 
dysfunction and behavioral or externalizing dysfunction. The RC scales, are a group of 
135 
9 scales that assess demoralization, somatic complaints, low positive emotions, 
136 
cynicism, antisocial behavior, ideas of persecution, dysfunctional negative emotions, 
137 
aberrant experiences, and hypomanic activation.  The SP scales are 23 and they are 
138 
divided in four groups for the assessment of somatic/cognitive problems, internalizing 
139 
problems, externalizing problems, and interpersonal problems. Reliability and validity 
140 
of this instrument are good, and extensive data can be consulted in the MMPI-2-RF 
141 
Technical Manual (Tellegen & Ben-Porath, 2008/2009). T scores of ≥65 are considered 
142 




 All the participants were assessed with all the above-mentioned questionnaires 
145 
in a face-to-face interview. All the smokers gave their informed consent for 
146 
participation, and the study was authorized by the Bioethics Committee. 
147 
 After the assessment, participants started the Smoking Cessation Program 
148 
(Becoña, 2007). It is a cognitive-behavioral intervention consisting of six sessions (one 
149 




their availability. It contains the following elements: treatment contract, self-report and 
151 
graphic representation of cigarette consumption, information about tobacco, stimulus 
152 
control, activities to avoid the withdrawal syndrome, physiological feedback (CO in 
153 
expired air) on cigarette consumption, nicotine fading (change of cigarette brands each 
154 




 Face to face follow-ups were conducted 6 and 12 months after treatment. In 
157 




2.4. Abstinence measures 
160 
We used the Micro
+ 
Smokerlyzer ® (Bedfont Scientific Ltd, Sittingbourne, UK) 
161 
to measure carbon monoxide (CO) in expired air, to corroborate self-reported abstinence 
162 
at the end of treatment and at the 6- and 12-month follow-ups (cut-off point of < 10ppm 
163 
to be considered a non-smoker) (West, Hajek, Stead, & Stapleton, 2005). A participant 
164 
was considered abstinent when he or she reported not smoking for at least 24 hours at 
165 
the end of treatment, during the 7 days prior to the date of the 6-month follow-up, and 
166 
30 days prior to the 12-month follow-up (Velicer, Prochaska, Rossi, & Snow, 1992).  
167 
2.5. Statistical Analysis  
168 
 To determine sample characteristics, we conducted descriptive statistical 
169 
analysis. To test the differences between abstainers and smokers at the end of treatment 
170 




V effect size was presented when chi-square was significant). We used binary logistic 
172 
regression analysis with a stepwise procedure to identify the predictive value of 
173 




characteristics and nicotine dependence, on smoking status (1 = Yes, 0 = No) at the end 
175 
of treatment and at 6- and 12-month follow-ups.  
176 
 All analyses were performed with the SPSS software version 20. The 
177 




 Treatment outcomes are reported in Table 2.  
180 
--------------------------------------------Table 2 about here--------------------------------------- 
181 
Bivariate analyses (Table 2) indicated that there were significant differences 
182 
according to age, nicotine dependence, and several scales of the MMPI-2-RF at the 
183 
different assessment time points. Sex, educational level, and social class were not 
184 
significant. With regard to the association between the MMPI-2-RF scales and smoking 
185 
status, participants with T-scores ≥ 65 on Emotional/ Internalizing Dysfunction (EID), 
186 
Demoralization (RCd), Ideas of Persecution (RC6), Malaise (MLS), Cognitive 
187 
Complaints (COG), Self-Doubt (SFD), Inefficacy (NFC), Anxiety (AXY), 
188 
Disaffiliativeness (DSF), and Psychoticism-Revised (PSYC-r) were more likely to 
189 
smoke at the end of treatment.  
190 
Regarding the 6- and 12-month follow-ups, there were a higher percentage of 
191 
smokers than non-smokers with T-scores ≥ 65 on Somatic Complaints (RC1) and 
192 
Neurological Complaints (NUC).  
193 
The results of the binary logistic regression adjusted for age and nicotine 
194 
dependence, showed that participants with T-scores < 65 on Disaffiliativeness (DSF) 
195 
(OR = 0.145) had a higher likelihood of smoking at the end of treatment. No scale was 
196 
significant in the prediction at the 6-month follow-up (Table 3). At the 12-month 
197 
follow-up, participants with a T-score ≥ 65 on Neurological complaints (NUC) (OR = 
198 








The aim of the present study was to analyze the utility of the MMPI-2-RF scales, 
202 
as indicators of psychopathology, to predict the result of a treatment to quit smoking at 
203 
the end of treatment and at the 6- and 12-month follow-ups.  
204 
At the end of treatment, there was a relationship between continuing to smoke 
205 
and T-scores ≥ 65 on the scales EID, RCd, RC6, MLS, COG, SFD, NFC, AXY, DSF, 
206 
and PSYC-r. At the 6- and 12-month follow-ups, smoking was associated with T-scores 
207 
≥ 65 on the RC1 and NUC scales. Moreover, T scores ≥ 65 on DSF predicted being 
208 




These results differ from those of Ames et al. (2005) who found that high scores 
211 
on Scale 7 (Psychasthenia, Pt) and on Psychopathology Five-Negative 
212 
Emotionality/Neuroticism (NEGE), referred to as Dysfunctional Negative Emotions 
213 
(RC7) and Negative Emotionality/Neuroticism-revised (NEGE-r), respectively, in the 
214 
most recent version of the MMPI-2-RF, were predictive of a lower likelihood of 
215 
tobacco abstinence 6 months after receiving smoking cessation treatment. In contrast to 
216 
our study, these authors only used some of the MMPI scales to assess traits such as 
217 
anxiety, depression, pessimism, and neuroticism, which could explain the discrepancies 
218 
with our results. 
219 
It is difficult to make comparisons with previous studies because many of them 
220 
used very specific samples like people with a heart transplantation (Basile et al., 2004), 
221 
submarine crews (Tappan & Weybrew, 1982), or students (Andrucci et al., 1989; Evans 
222 




found high levels of psychopathology, as indicated by high scores on the MMPI in 
224 
treatment seeking smokers (Ames et al., 2005; Cottraux et al., 1986).  
225 
Regarding the H-O scales, a T-score ≥ 65 on EID scale is related to not quitting 
226 
at the end of treatment. Van der Heijden et al. (2012) also found high mean scores on 
227 
this scale in 205 alcohol-dependent patients. These results could be a reflection of the 
228 
emotional distress of people requesting treatment for substance use (Grant, Stinson et 
229 




Within the group of RC scales, at the end of treatment, the results showed that T-
232 
scores ≥ 65 on RCd and RC6 are related to smoking. As noted by Forbey and Ben-
233 
Porath (2007), people coming for substance abuse treatment often experience anxiety 
234 
and distress and, as a result, they obtain high scores on multiple clinical scales, 
235 
including some unexpected ones like the scale currently known as RC6, which is a 
236 
measure of ideas of persecution. Van der Heijden, Egger, Rossi, & Derksen (2012) also 
237 
found high mean scores on the RC6 scale in the sample of alcohol-dependent patients. 
238 
Although paranoid thoughts have been associated with the presence of psychotic 
239 
disorders (Purdon, Purser, & Goddard, 2011), they could be the result of ruminative 
240 
thinking (Brinker, Chin, & Wilkinson, 2014; Wolf et al., 2008), perhaps due to a low 
241 
mood or an underlying anxiety disorder, both frequent disorders in smokers (Grant, 
242 
Hasin, et al. 2004).  
243 
With regard to the 6- and 12-month follow-ups, high scores on the RC1 scale 
244 
were related to smoking, as Forbey and Ben-Porath (2007) had found in their study with 
245 
people in treatment for substance abuse. This scale assesses physical health problems. 
246 
Forbey and Ben-Porath concluded that the high scores were due to the age of the 
247 




sample (M = 41.80, SD = 10.78). It is known that smokers have a poorer physical 
249 




Within the SP scales, high scores on MLS, COG, SFD, NFC, AXY, and DSF 
252 
were associated with smoking at the end of treatment, and the NUC scale was related to 
253 
smoking at the 6- and 12-month follow-ups. These results cannot be compared with 
254 
previous studies because, so far, no study has used the SP scales to assess smokers or 
255 
people who use other substances. We found that a T-score < 65 on DSF was associated 
256 
with a greater likelihood of smoking at the end of treatment, and a T-score ≥ 65 on NUC 
257 
was associated with a greater likelihood of smoking at the 12-month follow-up.  
258 
High scores on DSF describe a person who dislikes people or being around them 
259 
(Tellegen & Ben-Porath, 2008/2009), and this scale has been linked to schizoid 
260 
personality disorder (Ayearst et al., 2013; Ben-Porath, 2012; Tellegen & Ben-Porath, 
261 
2008/2009). Piñeiro, Fernández del Río, López-Durán, Martínez, and Becoña (2013) 
262 
found that people with schizoid personality disorder were more likely to maintain 
263 
abstinence at the 6- and 12-month follow-ups after smoking cessation treatment. Also, 
264 
Becoña, Fernández del Río, López-Durán, Piñeiro, and Martínez (2013) found that 
265 
people with schizoid personality disorder were less likely to be nicotine-dependent 
266 
smokers in a study with smokers of the general population. They concluded that 
267 
smokers with schizoid personality disorder are more likely to experiment with tobacco 
268 
but less likely to be dependent, which increases the likelihood of success when quitting 
269 
(Fiore et al., 2008). In addition, schizoid personality disorder is characterized by a low 
270 
need for stimulation (Ekleberry, 2009; Samuel & Widiger, 2008) and for social 
271 




(Piñeiro et al., 2013) and would therefore present fewer problems to stop smoking and 
273 
remain abstinent.  
274 
 Regarding the NUC scale, T-scores ≥ 65 predicted smoking at the 12-month 
275 
follow-up. It has been suggested that a high score on this scale does not necessarily 
276 
imply a neurological impairment (Ben-Porath, 2012; Bolinger, Reese, Suhr, & Larrabee, 
277 
2014) but rather the presence of somatic and psychological problems (Bolinger et al., 
278 
2014). In fact, high scores on this scale in patients with major depressive disorder have 
279 
been found (Sellbom, Bagby, Kushner, Quilty, & Ayearst, 2012), and a positive 
280 
correlation with rumination (Brinker et al., 2014), so it is possible that the relationship 
281 
between high scores on the NUC scale and smoking is due to negative mood rather than 
282 
to a neurological impairment.  
283 
Finally, in the PSY-5 scales, we found an association between T-scores ≥ 65 on 
284 
PSYC-r and tobacco consumption. Ames et al. (2005) used the Negative 
285 
Emotionality/Neuroticism (NEGE) scale as a measure of neuroticism, finding that high 
286 
scores on this scale were predictors of tobacco use 6 months after smoking cessation 
287 
treatment. However, these authors did not use the other PSY-5 scales in their study. In 
288 
our study, it is likely that the results are consistent with our previous comments about 
289 
the relationship between persecutory ideas and low affect (Brinker et al., 2014; Wolf et 
290 
al., 2008). Freeman (2007) estimates that between 10% and 15% of the general 
291 
population experience paranoid thoughts regularly and, based on reviewed studies, this 
292 
could be due to negative affect and anxiety. We also now know that there is a 
293 
relationship between negative affect and anxiety and smoking (Grant, Hasin et al., 
294 






 This study is not without limitations. The ability to generalize the results to 
297 
smokers from the general population is limited because we used a clinical sample of 
298 
patients who received an intervention to quit smoking. This type of sample has different 
299 
characteristics, for example, a greater nicotine dependence (Fagerström et al., 1996). 
300 
Additionally, the data are based on a self-report questionnaire, although the nine 
301 
Validity scales allow reducing biases such as social desirability or distortions of recall. 
302 
In addition, the MMPI-2-RF is a screening tool that does not allow performing 
303 
diagnoses. Moreover, we could not establish comparisons with other studies on the 
304 
relationship between psychopathology assessed with this instrument and tobacco use, 
305 
due to its recent publication. Finally, participants with a severe mental disorder were 
306 
excluded from the total sample, as they follow a different smoking cessation treatment 
307 
protocol with more sessions.  
308 
 Despite these limitations, this study adds more knowledge about the MMPI-2-
309 
RF and shows its utility in the field of the treatment of tobacco use. In addition, we used 
310 
a sample of smokers who attended a psychological treatment to quit smoking and who 
311 
were assessed longitudinally for one year, using biochemical validation of tobacco 
312 




 The results of this study indicate that the MMPI-2-RF is a suitable instrument for 
315 
the assessment of psychopathology and the prediction of the results of a treatment to 
316 
quit smoking. Therefore, it can be important for the design and improved outcomes of 
317 
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Table 1. Sociodemographic characteristics of the sample of smokers (N = 281). 
489 
 Mean SD 
Age 41.80 10.78 
 n % 
Age (grouped)   
   ≤ 40  123 43.8 
   > 40 158 56.2 
Gender   
  Male 111 39.5 
  Female 170 60.5 
Marital status   
   Single 94 33.5 
   Married/living with partner 146 52.0 
   Separated or divorced 33 11.7 
   Widowed 8 2.8 
Educational level   
   Elementary  65 23.1 
   Middle studies 96 34.2 
   Higher studies 120 42.7 
Social class   
   Low 66 23.5 
   Medium 188 66.9 





Table 2. Comparison of age, nicotine dependence, and MMPI-2-RF scales between smokers and abstainers at the end of treatment and at 
the 6- and 12- months follow-ups.  
 End of treatment 6-month follow-up 12-month follow-up 
 Smokers 
(n = 106) 
Abstainers 
(n = 175) 
  
Smokers 
(n = 188) 
Abstainers 
(n = 93) 
  Smokers 
(n = 202) 
Abstainers 
(n = 79) 
  
 n % n % 2 Cramer’s V n % n % 2 Cramer’s V n % n % 2 Cramer’s V 
Age                   
  ≤ 40 34 27.6 89 72.4 9.46** 0.18** 79 62.4 44 35.8 0.71  85 69.1 38 30.9 0.84  
   > 40 72 45.6 86 54.4   109 69.0 49 31.0   117 74.1 41 25.9   
FTND                   
   < 6 42 28.2 107 71.8 12.27*** 0.21*** 86 57.7 63 42.3 12.09** 0.21** 99 66.4 50 33.6 4.65* 0.13* 
   ≥ 6 64 48.5 68 51.5   102 77.3 30 22.7   103 78.0 29 22.0   
MMPI-2-RF (T ≥ 65)                   
  EID 24 22.6 23 13.1 4.28* 0.12* 34 18.1 13 14.0 0.75  38 18.8 9 11.4 2.24  
  RCd 26 24.5 23 13.1 5.94* 0.15* 37 19.7 12 12.9 1.99  40 19.8 9 11.4 2.79  
  RC1 28 26.4 30 17.1 3.47  46 24.5 12 12.9 5.08* 0.13* 48 23.8 10 12.7 4.28* 0.12* 
  RC6 13 12.3 6 3.4 8.18** 0.17** 15 8.0 4 4.3 1.34  16 7.9 3 3.8 1.53  
  MLS 28 26.4 29 16.6 3.96* 0.12* 43 22.9 14 15.1 2.35  44 21.8 13 16.5 0.99  
  NUC 21 19.8 21 12.0 3.17  35 18.6 7 7.5 6.02* 0.15* 39 19.3 3 3.8 10.75** 0.20** 
 
 23 
  COG 27 25.5 23 13.1 6.86** 0.16** 39 20.7 11 11.8 3.38  41 20.3 9 11.4 3.09  
  SFD 20 18.9 17 9.7 4.83* 0.14* 28 14.9 9 9.7 1.48  29 14.4 8 10.1 0.89  
  NFC 19 17.9 14 8.0 6.27* 0.15* 26 13.8 7 7.5 2.39  25 12.4 8 10.1 0.28  
  AXY 21 19.8 17 9.7 5.76* 0.14* 28 14.9 10 10.8 0.91  31 15.3 7 8.9 2.04  
  DSF 13 12.3 3 1.7 13.68*** 0.22*** 13 6.9 3 3.2 1.58  14 6.9 2 2.5 2.05  
  PSYC-r 7 6.6 2 1.1 6.35* 0.15 8 4.3 1 1.1 2.03  9 4.5 0 0.0 3.64  
 (1) Fisher's exact test was used when the expected values of at least 20% of the cells were less than 5. 
 EID: Emotional/Internalizing Dysfunction; RDd: Demoralization; RC1: Somatic Complaints; RC6: Ideas of Persecution; MLS: Malaise; NUC: Neurological Complaints; COG: Cognitive Complaints; SFD: 
Self-Doubt; NFC: Inefficacy; AXY: Anxiety; DSF: Disaffiliativeness; PSYC-r: Psychoticism-Revised. 
* p ≤ .05. **p ≤ .01. ***p ≤ .00.
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 AOR 95% CI p-value 
End of treatment    
     DSF (T ≥ 65) 0.15 0.035-0.604 .008 
12-month follow-up    
     NUC (T ≥ 65) 5.60 1.476-21-250 .011 
AOR: Adjusted Odd Ratio for age and initial level of nicotine dependence.  
3 
DSF: Disaffiliativeness; NUC: Neurological Complaints 
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